Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Patients with diabetes mellitus (DM) are prone to a diffuse and rapidly progressive form of atherosclerosis, which increases their likelihood of requiring revascularization. However, the unique pathophysiology of atherosclerosis in patients with DM modifies the response to arterial injury, with profound clinical consequences for patients undergoing percutaneous coronary intervention (PCI). Multiple studies have shown that DM is a strong risk factor for restenosis following successful balloon angioplasty or coronary stenting, with greater need for repeat revascularization and inferior clinical outcomes. Early data suggest that drug eluting stents reduce restenosis rates and the need for repeat revascularization irrespective of the diabetic state and with no significant reduction in hard clinical endpoints such as myocardial infarction and mortality. For many patients with 1- or 2-vessel coronary artery disease, there is little prognostic benefit from any intervention over optimal medical therapy. PCI with drug-eluting or bare metal stents is appropriate for patients who remain symptomatic with medical therapy. However, selection of the optimal myocardial revascularization strategy for patients with DM and multivessel coronary artery disease is crucial. Randomized trials comparing multivessel PCI with balloon angioplasty or bare metal stents to coronary artery bypass grafting (CABG) consistently demonstrated the superiority of CABG in patients with treated DM. In the setting of diabetes CABG had greater survival, fewer recurrent infarctions or need for re-intervention. Limited data suggests that CABG is superior to multivessel PCI even when drug-eluting stents are used. Several ongoing randomized trials are evaluating the long-term comparative efficacy of PCI with drug-eluting stents and CABG in patients with DM. Only further study will continue to unravel the mechanisms at play and optimal therapy in the face of the profoundly virulent atherosclerotic potential that accompanies diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Optimal Medical Therapy with or without PCI for Stable Coronary Disease
Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070829 · Cited by 4,699 · cited 1×
“The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial also showed that percutaneous intervention with optimal medical therapy was no better than optimal medical therapy alone for patients with stable CAD in general and for a subgroup of patients with DM (34% of patients enrol…”
Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961 · cited 1×
“Hyperglycemia promotes inflammation [35,36], induces the production of growth factors that promote restenosis [27] and increases matrix gene transcriptions [37].”
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939
Young, L. H., Wackers, F. J. T., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009) · JAMA · doi:10.1001/jama.2009.476 · Cited by 809 · cited 1×
“Furthermore, in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study, a prospective randomized trial evaluating outcomes after screening for asymptomatic CAD in type 2 patients with diabetes, cardiac event rates were not significantly reduced by myocardial perfusion imaging screening for myocardial ischemi…”
InfluentialWiviott, S. D., Braunwald, E., Angiolillo, D. J., Meisel, S., Dalby, A. J., Verheugt, F. W. A., Goodman, S. G., Corbalan, R., Purdy, D. A., Murphy, S. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.791061 · Cited by 754
Overexpression of Fibronectin Induced by Diabetes or High Glucose: Phenomenon With a Memory
Roy, S., Sala, R., Cagliero, E., & Lorenzi, M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.1.404 · Cited by 409 · cited 1×
“Hyperglycemia promotes inflammation [35, 36], induces the production of growth factors that promote restenosis [27] and increases matrix gene transcriptions [37].”
Alderman, E. L., Corley, S. D., Fisher, L. D., Chaitman, B. R., Faxon, D. P., Foster, E. D., Killip, T., Sosa, J. A., & Bourassa, M. G. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90429-5 · Cited by 350
Stettler, C., Allemann, S., Wandel, S., Kastrati, A., Morice, M. C., Schomig, A., Pfisterer, M. E., Stone, G. W., Leon, M. B., Lezo, J. S. D., et al. (2008) · BMJ · doi:10.1136/bmj.a1331 · Cited by 320 · cited 15×
“For example, in the Swedish Coronary Angiography and Angioplasty Registry, the numbers needed to treat patients with diabetes with DES to avoid one additional restenosis per year with BMS ranged from 21 to 47 lesions in patients treated with one stent and 11 to 27 in patients with multiple stents [56].”
InfluentialDiabetic and Nondiabetic Patients With Left Main and/or 3-Vessel Coronary Artery Disease
Banning, A. P., Westaby, S., Morice, M.-C., Kappetein, A. P., Mohr, F. W., Berti, S., Glauber, M., Kellett, M. A., Kramer, R. S., Leadley, K., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.057 · Cited by 290 · cited 1×
“Although DES reduce restenosis in comparison with bare-metal stents in patients with diabetes [60], DES studies have consistently shown higher repeat revascularization rates after PCI compared with surgical revascularization [83, 96].”
Cited by
Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes
Thiruvoipati, T. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i7.961 · Cited by 439
Restenosis after PCI. Part 1: pathophysiology and risk factors
Jukema, J. W., Verschuren, J. J. W., Ahmed, T. A. N., & Quax, P. H. A. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.132 · Cited by 299
Deb, S., Wijeysundera, H. C., Ko, D. T., Tsubota, H., Hill, S., & Fremes, S. E. (2013) · JAMA · doi:10.1001/jama.2013.281718 · Cited by 277
Coronary Artery Disease and Diabetes Mellitus
Aronson, D., & Edelman, E. R. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.04.001 · Cited by 222
Self-citationKushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0603-x · Cited by 48
Metadata
- Authors
- Aronson, D., & Edelman, E. R.
- Venue
- Reviews in Endocrine and Metabolic Disorders
- Published
- 2010-03
- Volume
- 11
- Issue
- 1
- Pages
- 75-86
- ISSN
- 1389-9155 (ISSN-L)
- 1573-2606
- OpenAlex
- W1585876416
- Cited by
- 88
- References
- 12
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting. https://app.cochat.ai/papers/10.1007/s11154-010-9135-3
- The paper
- Aronson, D., & Edelman, E. R. (2010). Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-010-9135-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.